FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease

Cancer

Volumn 107, Issue 11, 2006, Pages 2678-2687

  Kostakoglu, Lale ^a   Goldsmith, Stanley J ^b   Leonard, John P ^b   Christos, Paul ^b   Furman, Richard R ^b   Atasever, Tamer ^b   Chandramouly, Angely ^b   Verma, Sumeet ^b   Kothari, Pratichi ^b   Coleman, Morton ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Diffuse large cell lymphoma; Early response; FDG PET; Hodgkin disease; Therapy response

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN DERIVATIVE; DOXORUBICIN; FLUORODEOXYGLUCOSE; HYDROXYDAUNORUBICIN; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFECTIOUS COMPLICATION; LARGE CELL LYMPHOMA; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREDNISONE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 33751576028     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22276     Document Type: Article

References (27)

1. 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments? Cancer. 2006;107:1425-1428.
2. Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM. Hodgkin's disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999.
3. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
4. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
5. Hasenclever D; Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;39:1506-1514.
6. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
7. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
8. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non- Hodgkin's lymphoma. Haematologica. 2000;85:613-618.
9. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-1363.
10. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after 2 to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523.
11. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381.
12. Hutchings M, Loft A, Hansen M, et al. FDG-PET after 2 cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCl Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
14. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636.
15. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19:414-419.
16. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol. 2001;12:29-37.
17. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115:793-800
18. Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98:2930-2934.
19. Cremerius U, Fabry U, Neuerburg J, et al. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphomas. Nuklearmedizin. 2001;40:23-30.
20. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004;91:850-854.
21. Juweid ME, Wiseman G, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyclucose positron emission tomography. J Clin Oncol. 2005;23:4652-4661.
22. Freudenberg LS, Antoch G, Schütt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325-329.
23. Armitage JO, Weisenburger DD, Hutchins M. Chemotherapy for diffuse large-cell lymphoma - rapidly responding patients have more durable remissions. J Clin Oncol. 1986;4:160-164.
24. Engelhard M, Meusers P, Brittinger G. Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/1MVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol. 1991;2:177-180.
25. Haq R, Sawka CA, Franssen E. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: A literature review. J Clin Oncol. 1994;12:1074-1084.
26. Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol. 2002;13 suppl 1:86-91.
27. Moller MB, Pedersen NT and Christensen BE. Factors Predicting Long-Term Survival in Low-Risk Diffuse Large B-Cell Lymphoma Am J Hematol. 2003;74:94-98.